MAPK8 and neoplasm: ADT induces a compensatory activation of MAPK or JNK signaling, combination of JNK inhibitor AS602801 with enzalutamide synergistically inhibits PCa cell proliferation, invasion, and migration in vitro and xenograft tumor development in mouse models [99].